Business context and reporting period
Zoetis Inc. filed this Form 10-K for the fiscal year ended December 31, 2022; it reports annual results, not standalone fourth-quarter results. Zoetis is a global animal-health company selling medicines, vaccines, diagnostics and related products across companion animals and livestock. It reports U.S. and International segments. The filing was signed February 14, 2023.
Revenue was diversified by geography and species: companion-animal products generated $5.203 billion (64% of revenue), livestock products $2.791 billion (35%), and contract manufacturing and human health $86 million (about 1%). The five largest product lines generated approximately 37% of revenue; the ten largest generated 49%.
Financial results and liquidity
| Metric | 2022 | 2021 | Change |
|---|---|---|---|
| Revenue | $8.080 billion | $7.776 billion | +4% reported; +8% operational |
| Net income attributable to Zoetis | $2.114 billion | $2.037 billion | +4% |
| Diluted EPS | $4.49 | $4.27 | +5% |
| Adjusted net income (non-GAAP) | $2.297 billion | $2.240 billion | +3% |
| Adjusted diluted EPS (non-GAAP) | $4.88 | $4.70 | +4% |
| Operating cash flow | $1.912 billion | $2.213 billion | Down $301 million |
| Capital expenditures | $586 million | $477 million | Up $109 million |
Foreign exchange reduced reported revenue growth by about 4 percentage points. Gross margin, calculated from reported revenue and cost of sales, was approximately 69.6%, versus 70.4% in 2021; cost of sales rose 7% amid higher manufacturing, freight and import costs, foreign exchange effects and inventory charges. SG&A was broadly flat at $2.009 billion, while R&D increased 6% to $539 million. The effective tax rate rose to 20.5% from 18.2%. Net income margin was approximately 26.2% in both years.
Companion-animal revenue increased 11% to $5.203 billion, led by parasiticides, dermatology and new products. Livestock revenue declined 7% to $2.791 billion. U.S. revenue rose 7% to $4.313 billion; International revenue increased 1% reported, or 9% operationally, to $3.681 billion. U.S. segment earnings were $2.763 billion and International segment earnings were $1.990 billion; these are segment measures, not consolidated net income.
Cash and cash equivalents were $3.581 billion at year-end. Working capital was $4.339 billion versus $5.133 billion, and the current ratio was 2.37 versus 3.86; the change partly reflects $1.350 billion of debt classified as current. Principal debt outstanding was $8.0 billion, with $1.350 billion due in 2023; the company redeemed that maturity on February 1, 2023, using proceeds from its November 2022 issuance of $1.350 billion in senior notes. The year-end balance sheet reported $6.552 billion of long-term debt and $1.350 billion current debt. The $1.0 billion revolving facility was undrawn, and Zoetis reported compliance with its covenants.
Cash used in investing activities was $883 million, including $312 million for acquisitions. Cash used in financing was $904 million, including $1.594 billion of share repurchases and $611 million of dividends paid. Zoetis repurchased 9.5 million shares during 2022. Its dividend declared per share was $1.35, up from $1.075 in 2021.
Material changes, outlook and risks
- Management attributed operational revenue growth mainly to new products, price increases and dermatology products, partly offset by declines in other in-line products. The company’s two largest product lines, Simparica/Simparica Trio and Apoquel, contributed approximately 12% and 10% of revenue, respectively.
- Manufacturing constraints affected Simparica Trio and components for Librela and Solensia, limiting availability and delaying some market launches. Management said some supply challenges were expected to continue in 2023.
- Livestock weakness reflected generic competition, supply constraints, higher producer input costs and regional market conditions. International results also faced substantial currency headwinds. Generic competition has pressured products including Draxxin and ceftiofur products; the filing identifies additional patent expirations and potential generic entries.
- Russia’s invasion of Ukraine did not materially affect 2022 results, and management did not expect a material effect going forward. The filing discusses continuing monitoring of COVID-19, economic conditions and supply-chain risks. Zoetis provided no specific numerical financial guidance in the supplied filing text.
- Key risks include dependence on leading products; product safety, quality or efficacy issues; competition and generic entry; supply interruptions; foreign-exchange movements; inflation and customer cost sensitivity; disease outbreaks, weather and climate impacts; restrictions on livestock antibacterials; regulatory and intellectual-property challenges; cybersecurity and privacy risks; and substantial indebtedness.
- Unusual or notable items included $47 million of certain asset impairment charges, mainly involving diagnostics, poultry, cattle and swine assets and China manufacturing consolidation, as well as $11 million of restructuring and acquisition-related costs. Adjusted results exclude specified purchase-accounting, acquisition-related and significant items and are non-GAAP measures.
- Legal proceedings were described as ordinary-course matters; management said it considered a material adverse effect on financial position remote, but could not estimate reasonably possible losses above accruals. A dispute related to alleged feed contamination was effectively ended after Michigan’s Supreme Court denied further appeal in January 2023. A European Commission/Belgium tax matter remained pending; no potential benefit was recorded at year-end.
Important facts for investors to verify
- Whether manufacturing and component constraints persist in 2023, particularly for Simparica Trio, Librela and Solensia, and how they affect sales and launch timing.
- How much revenue and profit are exposed to the leading product lines and how generic competition or patent expirations affect those franchises.
- Whether price increases can offset higher production, freight and input costs without weakening customer demand or margins.
- Cash generation and working-capital trends, including the effect of inventory investment, acquisitions, repurchases and dividends.
- Debt maturities, refinancing costs and interest-rate exposure; confirm the February 2023 repayment of the 2023 notes and the resulting debt profile.
- Potential outcomes of tax and legal contingencies, foreign-exchange exposure, and the operational and financial impact of regulatory or environmental developments.